Arcutis Biotherapeutics, Inc.
ARQT
Classificação em ações
#3954
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Preço da ação
$32.83
Valor de mercado
$4.13B
Variação (1 dia)
2.93%
Variação (1 ano)
57.21%
País
US
Negociar Arcutis Biotherapeutics, Inc. (ARQT)
Categoria
Healthcare
Lucros da Arcutis Biotherapeutics, Inc. (ARQT)
Lucros em Jun 2026 TTM: $29.30M
De acordo com os últimos relatórios financeiros da Arcutis Biotherapeutics, Inc., os ganhos atuais da empresa são de $29.30M. Em 2023, a empresa teve ganhos de $-259.03M, um aumento em relação a aos ganhos de 2022, que foram de $-311.46M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Arcutis Biotherapeutics, Inc. de 2017 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $29.30M | -121.02% |
| 2024 | $-139.39M | -46.19% |
| 2023 | $-259.03M | -16.83% |
| 2022 | $-311.46M | 50.93% |
| 2021 | $-206.36M | 52.09% |
| 2020 | $-135.68M | 223.07% |
| 2019 | $-42.00M | 118.10% |
| 2018 | $-19.26M | 286.80% |
| 2017 | $-4.98M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | 17,904.30% |
US
|
|
| $-3.09B | -10,636.56% |
US
|
|
| $-4.02B | -13,808.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 6,557.96% |
NL
|
